{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:13:03Z","timestamp":1774743183864,"version":"3.50.1"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec id=\"ab-doi220036-4\"><jats:title>Importance<\/jats:title><jats:p>There is an increasing body of literature that supports the use of rituximab as a first-line steroid-sparing agent in pemphigus vulgaris. However, the cost of rituximab is substantial compared with conventional agents, and there are limited health economic data to justify its use.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi220036-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the cost-effectiveness of rituximab biosimilars relative to mycophenolate mofetil as a first-line steroid-sparing agent for moderate to severe pemphigus vulgaris.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi220036-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>A cost-utility analysis over a 24-month time horizon was conducted from the perspective of the Australian health care sector using a modeled cohort of treatment-naive adult patients with moderate to severe pemphigus vulgaris. A Markov cohort model was constructed to simulate disease progression following first-line treatment with rituximab biosimilars or mycophenolate mofetil. The simulated cohort transitioned between controlled disease, uncontrolled disease, and death. Efficacy and utility data were obtained from available published literature. Cost data were primarily obtained from published government data. One-way and probabilistic sensitivity analyses were performed to assess uncertainty. Primary outcomes were the changes in cost and quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) over the 24 months.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi220036-7\"><jats:title>Interventions<\/jats:title><jats:p>Rituximab biosimilars and mycophenolate mofetil.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi220036-8\"><jats:title>Results<\/jats:title><jats:p>The simulated cohort of treatment-naive patients had a mean age of 50.8 years, a female-to-male ratio of 1.24, and moderate to severe disease as classified by the Harman criteria. First-line rituximab biosimilars were associated with a cost reduction of AU$639 and an improvement of 0.07 QALYs compared with mycophenolate mofetil, resulting in an ICER of \u2212AU$8818\/QALY. Rituximab biosimilars were therefore more effective and less costly compared with mycophenolate mofetil. Sensitivity analyses demonstrated that rituximab biosimilars remained cost-effective across a range of values for cost, utility, and transition probability input parameters and willingness-to-pay thresholds.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi220036-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cost-utility analysis, rituximab biosimilars were cost-effective compared with mycophenolate mofetil for moderate to severe pemphigus vulgaris. Further investigation into its cost-effectiveness over a longer time horizon is necessary, but the favorable results of this study suggest that the high acquisition costs of rituximab biosimilars may be offset by its effectiveness and provide economic evidence in support of its listing on the Pharmaceutical Benefits Scheme for pemphigus vulgaris.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.2878","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T15:32:29Z","timestamp":1658935949000},"page":"1013","source":"Crossref","is-referenced-by-count":9,"title":["Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris"],"prefix":"10.1001","volume":"158","author":[{"given":"Michelle K. Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia"},{"name":"South West Sydney Clinical Campuses, University of New South Wales, Liverpool, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vissapragada","sequence":"additional","affiliation":[{"name":"Discipline of Surgery, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, South Australia, Australia"},{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, South Australia, Australia"},{"name":"Department of Surgery, Flinders Medical Centre, Bedford Park, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Bulamu","sequence":"additional","affiliation":[{"name":"Discipline of Surgery, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, South Australia, Australia"},{"name":"Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monisha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia"},{"name":"South West Sydney Clinical Campuses, University of New South Wales, Liverpool, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Werth","sequence":"additional","affiliation":[{"name":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania"},{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deshan Frank","family":"Sebaratnam","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia"},{"name":"South West Sydney Clinical Campuses, University of New South Wales, Liverpool, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"3","key":"doi220036r1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bjd.14647","article-title":"Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment.","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi220036r2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/bjd.13848","article-title":"Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis.","volume":"173","author":"Rencz","year":"2015","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi220036r3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjd.2019.180.issue-4","article-title":"Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus.","volume":"180","author":"Tam\u00e1si","year":"2019","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi220036r4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/jdv.v33.11","article-title":"Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus.","volume":"33","author":"Hajdu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi220036r5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clindermatol.2011.03.016","article-title":"Quality of life in patients with bullous dermatoses.","volume":"30","author":"Sebaratnam","year":"2012","journal-title":"Clin Dermatol"},{"issue":"2","key":"doi220036r6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities.","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"issue":"6","key":"doi220036r7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jamadermatol.2015.5240","article-title":"Costs of care for hospitalization for pemphigus in the United States.","volume":"152","author":"Hsu","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi220036r8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40257-019-00497-9","article-title":"Rituximab: a review in pemphigus vulgaris.","volume":"21","author":"Frampton","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"doi220036r9","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.v34.9","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV).","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi220036r10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/edm.09.45","article-title":"Treatment of pemphigus vulgaris and pemphigus foliaceus.","volume":"4","author":"Sebaratnam","year":"2009","journal-title":"Expert Rev Dermatol"},{"issue":"10083","key":"doi220036r11","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"doi220036r12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris.","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"doi220036r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107755","article-title":"Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study.","volume":"96","author":"Aryanian","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"doi220036r14","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/DDDT.S306046","article-title":"Rituximab therapy for treatment of pemphigus in Southeast Asians.","volume":"15","author":"Kanokrungsee","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"175","key":"doi220036r15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"doi220036r16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/09546634.2019.1617831","article-title":"Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.","volume":"32","author":"Toosi","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi220036r17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center.","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi220036r18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts.","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi220036r19","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.2017.177.issue-5","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017.","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"key":"doi220036r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs small molecules: drug costs and patient access.","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"key":"doi220036r21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vhri.2020.09.001","article-title":"Health technology assessment in Australia: the Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.","volume":"24","author":"Kim","year":"2021","journal-title":"Value Health Reg Issues"},{"issue":"4","key":"doi220036r22","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s11096-019-00853-z","article-title":"Use of non-formulary high-cost medicines in an Australian public hospital.","volume":"41","author":"Inglis","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"doi220036r23","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/ans.v91.9","article-title":"Cost-effectiveness in surgery: concepts of cost-utility analysis explained.","volume":"91","author":"Vissapragada","year":"2021","journal-title":"ANZ J Surg"},{"issue":"10","key":"doi220036r24","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/jdv.v33.10","article-title":"An introduction to the methods of decision-analytic modelling used in economic evaluations for dermatologists.","volume":"33","author":"McManus","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi220036r25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/bjd.v183.1","article-title":"Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs standard corticosteroid regimen: data from a national multicentre trial.","volume":"183","author":"H\u00e9bert","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220036r26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2310\/7750.2014.14092","article-title":"Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab.","volume":"19","author":"Heelan","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"doi220036r27","first-page":"S25","article-title":"Cost analysis of rituximab as an alternative first line adjuvant therapy to mycophenolate mofetil for moderate-to-severe pemphigus vulgaris.","volume":"134","author":"Jiang","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi220036r28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.","volume":"31","author":"Husereau","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"doi220036r29","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi220036r30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/jdv.2012.26.issue-7","article-title":"Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study.","volume":"26","author":"Ioannides","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi220036r31","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi220036r32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974\u20132018.","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"7662","key":"doi220036r36","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study.","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"sup1","key":"doi220036r37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/13696998.2021.2007705","article-title":"Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities.","volume":"24","author":"Choi","year":"2021","journal-title":"J Med Econ"},{"issue":"8","key":"doi220036r38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"37","key":"doi220036r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16370","article-title":"Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.","volume":"16","author":"Papaioannou","year":"2012","journal-title":"Health Technol Assess"},{"issue":"1","key":"doi220036r40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/03007995.2020.1846172","article-title":"Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis.","volume":"37","author":"Lopatina","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"doi220036r41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"doi220036r42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119683","article-title":"The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.","volume":"10","author":"Joensuu","year":"2015","journal-title":"PLoS One"},{"issue":"10067","key":"doi220036r43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(17)30053-3","article-title":"Cost-effectiveness of rituximab strategies in rheumatoid arthritis.","volume":"389","author":"Seror","year":"2017","journal-title":"Lancet"},{"issue":"10041","key":"doi220036r44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"doi220036r45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40258-019-00514-2","article-title":"Determining the baseline strategy in a cost-effectiveness analysis with treatment sequences.","volume":"18","author":"Viola","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"doi220036r46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40273-020-00980-w","article-title":"Quantitative evidence synthesis methods for the assessment of the effectiveness of treatment sequences for clinical and economic decision making: a review and taxonomy of simplifying assumptions.","volume":"39","author":"Lewis","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"doi220036r47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40273-016-0455-3","article-title":"Modeling treatment sequences in pharmacoeconomic models.","volume":"35","author":"Zheng","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"doi220036r48","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","article-title":"Dealing with time in health economic evaluation: methodological issues and recommendations for practice.","volume":"33","author":"O\u2019Mahony","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"doi220036r49","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","article-title":"The influence of time horizon on results of cost-effectiveness analyses.","volume":"17","author":"Kim","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"doi220036r50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population-based study.","volume":"132","author":"Huang","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi220036r51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus.","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"doi220036r53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12962-018-0103-1","article-title":"Cultural beliefs, utility values, and health technology assessment.","volume":"16","author":"Mahlich","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"doi220036r54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report.","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"doi220036r55","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jaad.2020.11.075","article-title":"Intraepithelial autoimmune blistering dermatoses: clinical features and diagnosis.","volume":"84","author":"Montagnon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220036r56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaad.2020.08.028","article-title":"Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.","volume":"85","author":"Lee","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220036r57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14737167.2020.1722104","article-title":"Disease burden of patients with pemphigus from a societal perspective.","volume":"21","author":"Brodszky","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"doi220036r58","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.6","article-title":"Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: a pilot study.","volume":"33","author":"Mazloom","year":"2020","journal-title":"Dermatol Ther"},{"key":"doi220036r59","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid.","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"doi220036r60","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamadermatol.2013.4972","article-title":"Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.","volume":"149","author":"Sebaratnam","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi220036r61","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bjd.2013.169.issue-5","article-title":"The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi220036r62","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/13696998.2019.1627362","article-title":"Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).","volume":"22","author":"Matza","year":"2019","journal-title":"J Med Econ"},{"issue":"10","key":"doi220036r63","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/17512433.2019.1670059","article-title":"What is novel in the clinical management of pemphigus.","volume":"12","author":"Bilgic","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"doi220036r64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.","volume":"28","author":"Cho","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi220036r65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus.","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220036r66","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/bjd.v186.3","article-title":"Ultralow-dose rituximab in pemphigus: a single-centre experience.","volume":"186","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi220036r67","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bjd.2014.170.issue-6","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220036r68","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v33.1","article-title":"Intralesional rituximab salvages refractory scalp lesions in a case of pemphigus vulgaris.","volume":"33","author":"Gupta","year":"2020","journal-title":"Dermatol Ther"},{"key":"doi220036r69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.intimp.2019.04.031","article-title":"Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: a randomized clinical trial.","volume":"73","author":"Iraji","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"doi220036r70","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris.","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi220036r71","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"doi220036r72","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1111\/bjd.v185.4","article-title":"Subcutaneous rituximab for autoimmune bullous diseases.","volume":"185","author":"Riquelme-Mc Loughlin","year":"2021","journal-title":"Br J Dermatol"},{"key":"doi220036r34","volume-title":"Comprehensive Dermatologic Drug Therapy: Expert Consult\u2014Online and Print","author":"Wolverton","year":"2012"},{"key":"doi220036r33","unstructured":"NSW Government. Public Health System Nurses\u2019 and Midwives\u2019 (State) Award 2021. Accessed November 1, 2021. https:\/\/www.health.nsw.gov.au\/careers\/conditions\/awards\/nurses.pdf"},{"key":"doi220036r35","unstructured":"Australian Bureau of Statistics. Life tables. Accessed November 1, 2021. https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-tables\/2017-2019"},{"key":"doi220036r52","unstructured":"Australian Bureau of Statistics. 2024.0\u2014Census of Population and Housing: Australia Revealed, 2016. Accessed May 3, 2022. https:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/Latestproducts\/2024.0Main%20Features22016"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2794713\/jamadermatology_chen_2022_oi_220036_1662573733.88375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:08:07Z","timestamp":1663772887000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2794713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.2878","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}